LOKELMA

LOKELMA effectively reduces and maintains a healthy potassium level in adults with hyperkalemia.

Lokelma, a medication used to treat hyperkalemia, has the potential to cause hypokalemia, resulting in low potassium levels. In clinical trials, it was found that 4.1% of individuals who were not undergoing dialysis and were prescribed Lokelma experienced hypokalemia.

Lokelma, when administered three times daily at a dosage of 10 g, resulted in a reduction of serum potassium by 0.7 mmol/L at 48 hours (p < 0.001 compared to placebo). A statistically significant reduction of 14% in potassium levels was observed just one hour after the first dose. Patients with higher initial potassium levels exhibited a more pronounced response to Lokelma.

In cases where hyperkalemia resolves within 48 hours of initiating Lokelma treatment, further medication may not be necessary as determined by your physician. However, if potassium levels remain elevated, your doctor may advise continuing with the medication for an extended period. It is safe to take Lokelma for long-term treatment.

If your blood potassium level drops too low, your treatment may be discontinued. It is important to inform your doctor or nurse if you are taking any medications that can affect your blood potassium levels, as your dosage of Lokelma may need to be adjusted.

You have the option to take Lokelma with or without food. However, it is important to take it separately from other medications (2 hours before or 2 hours after) as it may affect the effectiveness of other medications in your body.

Lokelma, also known as sodium zirconium cyclosilicate, belongs to the cation exchange resins drug class and is frequently prescribed for Hyperkalemia. The price of Lokelma oral powder for reconstitution, with a dosage of 5 g, can vary depending on the pharmacy you choose. On average, it costs approximately $311 for a supply of 11 powder for reconstitution.

To patients undergoing chronic hemodialysis, LOKELMA should only be given on days when dialysis is not scheduled. The suggested initial dosage is 5 g once daily on non-dialysis days. However, if a patient’s serum potassium level exceeds 6.5 mEq/L, it is advisable to begin with a dosage of 10 g once daily on non-dialysis days.

Complications of hyperkalemia include sudden onset of severe symptoms and life-threatening heart changes that can lead to a heart attack. If left untreated, even mild hyperkalemia can gradually damage the heart.

Limited data exists comparing Lokelma, a selective potassium cation trapping agent, and Kayexalate, an ion-exchange resin, for the treatment of acute hyperkalemia.

Taking this medication can lead to severe intestinal issues, which in rare cases can be life-threatening, such as bleeding or blockage.

To initially treat hyperkalemia, it is recommended to administer LOKELMA at a dose of 10 g three times a day for up to 48 hours. LOKELMA should be taken orally as a suspension in water. For ongoing treatment, the recommended dose is 10 g once daily.

Kayexalate, also known as sodium polystyrene, is a medication that is used to treat hyperkalemia, which is characterized by high levels of potassium in the blood. This medication functions as a cation-exchange resin, aiding the body in eliminating excess potassium.

You should drink the entire dose of Lokelma after mixing the powder with water. If you are unsure about how to take Lokelma, it is recommended to consult with your doctor or pharmacist. As for taking Lokelma with food, you have the option to take it with or without food.

Kayexalate, also known as Sodium polystyrene sulfonate, was approved in 1958 as a treatment for hyperkalemia. It works by exchanging sodium for potassium in the colon, effectively removing excess potassium from the body. This drug has been widely used in the treatment of hyperkalemia for many years.

While diarrhea was not observed as a side effect of Lokelma in clinical trials, it is important to note that other medications used to treat hyperkalemia in adults may cause diarrhea. Additionally, diarrhea can also be associated with hypokalemia, which is characterized by low potassium levels.

Sodium polystyrene sulfonate is administered to address hyperkalemia, a condition characterized by elevated potassium levels in the blood. Unlike other medications, sodium polystyrene sulfonate functions by passing through the intestines without being absorbed into the bloodstream.

To use Lokelma 10 Gram Oral Powder Packet, follow the instructions given by your doctor. Take this medication orally. If you are also taking other medications, make sure to take them either 2 hours before or 2 hours after taking Lokelma.

Kayexalate is the brand name for the generic drug sodium polystyrene sulfonate, which is available in powder form with a sodium content of 4.1mEq/g.

Results from the ZORA observational multi-country study, presented at the ASN 2023, demonstrate that the potassium binder Lokelma (sodium zirconium cyclosilicate) effectively treats hyperkalaemia (HK) in patients with chronic kidney disease (CKD) or heart failure (HF).

Lokelma, also known as sodium zirconium cyclosilicate, is a medication prescribed for the treatment of elevated blood potassium levels. However, it is important to note that Lokelma may result in a variety of side effects, ranging from mild to severe. These side effects can include the accumulation of fluid in different parts of the body and a decrease in blood potassium levels.

Possible symptoms of an allergic reaction include a skin rash, itching, hives, and swelling of the face, lips, tongue, or throat. Low potassium levels may cause muscle pain or cramps, unusual weakness or fatigue, a fast or irregular heartbeat, and constipation. Swelling of the ankles, hands, or feet and sudden weight gain are also potential symptoms.

Lokelma 10 g, given three times daily, effectively reduced serum potassium levels by -0.7 mmol/L at 48 hours compared to placebo (p < 0.001). Additionally, a significant 14% reduction in potassium levels was observed just one hour after the initial dose. Notably, patients with higher initial potassium levels exhibited a more pronounced response to Lokelma.

In cases where hyperkalemia resolves within 48 hours of initiating Lokelma treatment, further medication may not be necessary as determined by your physician. However, if potassium levels remain elevated, your doctor may advise continuing with the medication for an extended period. It is safe to take Lokelma for long-term treatment.

No, Lokelma does not cause diarrhea and constipation as side effects. However, if you already have digestive issues like severe constipation or intestinal blockages, taking Lokelma may exacerbate your symptoms. Severe diarrhea can also lead to electrolyte imbalances, including potassium loss.

Lokelma, which contains sodium, has the potential to cause swelling or rapid weight gain. It is important to note that this list of side effects is not exhaustive, and there may be others that occur. If you experience any side effects, it is recommended to contact your doctor for medical advice. Additionally, you can report any side effects to the FDA at 1-800-FDA-1088.

It is crucial to follow your healthcare provider’s instructions and take LOKELMA only on non-dialysis days.

After the administration of Lokelma, potassium levels begin to decrease within one hour. Studies have shown that it takes a median of 2.2 hours for potassium levels to return to normal. Additionally, over 90% of patients achieve normal potassium levels within 48 hours.

LOKELMA functions within the digestive tract by specifically binding to potassium and eliminating it from the body, preventing its entry into the bloodstream. This medication is specifically designed to solely target and remove potassium, without affecting calcium and magnesium levels.

LOKELMA successfully reduced potassium levels in patients with chronic kidney disease, heart failure, diabetes mellitus, and those undergoing RAAS inhibitor therapy.

Before initiating Lokelma treatment, it is crucial to inform your doctor about any existing severe constipation. This is because the effectiveness of the medication in reducing your potassium levels may be compromised. In such instances, your doctor may opt to address your constipation issue prior to commencing Lokelma therapy.

Lokelma is available in oral powder for reconstitution, injectable solution, and compounding powder for intravenous solution. Calcium gluconate is available in oral tablet form. Sodium bicarbonate is available in intravenous solution form. There are no specific brand names mentioned for these medications. Cal-G, Cal-GLU, and Kalcinate are brand names for calcium gluconate. Bell/ans and Neut are brand names for sodium bicarbonate.

After taking LOKELMA, your potassium levels will begin to decrease within one hour. The extent of the decrease will vary based on your initial potassium level. Typically, patients achieve normal potassium levels within 24 to 48 hours of starting treatment.

Water pills, also known as diuretics, aid in the elimination of excess potassium from your body. They function by stimulating your kidneys to produce more urine, which helps remove potassium. Potassium binders are typically available in powder form.

Possible side effects of this medication include sodium-related swelling and rapid weight gain.